Search - tctmd.com

Displaying 101 - 120 of 209

Sort: Relevancy | Date

‘Considerable’ Aortic Stenosis Burden in UK Begs Money and a Plan

News Daily News

‘Considerable’ Aortic Stenosis Burden in UK Begs Money and a Plan

Michael O'Riordan

January 28, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

COVID-19: TCTMD’s Dispatch for January Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for January Week 3

January 17, 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

As COVID-19 Drags on, the Cardiology Fallout May Haunt for Years

News Features

As COVID-19 Drags on, the Cardiology Fallout May Haunt for Years

December 16, 2021

British Medical Groups Express Concern About Inclisiran Rollout

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

COVID-19: TCTMD’s Dispatch for December Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for December Week 1

December 06, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

News Daily News

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

November 01, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery

News Daily News

AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery

Yael L. Maxwell

October 04, 2021

Even as COVID-19 Care Improved in NYC, Troponin Still Signaled Higher Mortality

News Daily News

Even as COVID-19 Care Improved in NYC, Troponin Still Signaled Higher Mortality

September 28, 2021

COVID-19: TCTMD’s Daily Dispatch for September Week 4

News Daily News

COVID-19: TCTMD’s Daily Dispatch for September Week 4

September 20, 2021

Heterozygous FH Diagnosed Late, Remains Undertreated

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.